Biogen (NASDAQ:BIIB) Price Target Lowered to $245.00 at The Goldman Sachs Group
Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by research analysts at The Goldman Sachs Group from $281.00 to $245.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target indicates a potential upside […]
Biogen (NASDAQ:BIIB – Get Free Report) had its price target decreased by research analysts at The Goldman Sachs Group from $281.00 to $245.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the biotechnology company’s stock. The Goldman Sachs Group’s price target indicates a potential upside […]
